Telmisartan (TRANSCEND) vs Placebo (TRANSCEND): TRANSCEND. Non-fatal Myocardial Infarction
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0386 | 0.0322 | 0.0462 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0488 | 0.0416 | 0.0571 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.0102 | -0.0207 | 0.000234 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.791 | 0.622 | 1.01 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.783 | 0.609 | 1.01 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Telmisartan (TRANSCEND) than on Placebo (TRANSCEND) | 98.1 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Telmisartan (TRANSCEND) | Telmisartan 80mg tablet, one tablet administered once daily in the morning. | 114 | 2,954 | OG000 | ClinicalTrials.gov |
| Group 2 | Placebo (TRANSCEND) | Telmisartan 80mg placebo tablet, one tablet administered once daily in the morning. | 145 | 2,972 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | TRANSCEND. Non-fatal Myocardial Infarction | ClinicalTrials.gov |
| Description | Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to the first event analysis of the endpoint non-fatal myocardial infarction. | ClinicalTrials.gov |
| Time frame | 56 months | ClinicalTrials.gov |
| Population | FAS of the TRANSCEND trial | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo. | ClinicalTrials.gov |
| NCT number | NCT00153101 | ClinicalTrials.gov |
| Phases | PHASE4 | ClinicalTrials.gov |
| Conditions | Cardiovascular Diseases | ClinicalTrials.gov |
| Interventions | Telmisartan, Combination of Telmisartan and Ramipril, Ramipril | ClinicalTrials.gov |
| Lead sponsor | Boehringer Ingelheim | ClinicalTrials.gov |
| Results first posted | 2009-08-25 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT00153101?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.